MannKind sends insulin to FDA

Share this article:

Two months after releasing Phase III data over its inhaled insulin, MannKind announced Monday it has resubmitted its FDA application for Afrezza.

The FDA rejected the drug three years ago when the manufacturer submitted data that predated an inhaler change.

Clearing the FDA would put Afrezza on previously trod ground. Pfizer abandoned its inhaled insulin Exubera following poor sales. Novo and Lilly have also left inhaled insulin efforts in the dust.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.